Indeed, the combined therapy of talazoparib, a PARPi useful to affect BRCA1/2-mutated HER2− BC [149], and BETi is under evaluation in Phase II clinical trials to reduce solid tumors that are difficult to treat and could easily metastasize [150]. The gene discussed is BRCA1; the disease is breast cancer.